Leukemia Clinical Trials

Showing 1201-1220 of 5,235 trials

Characteristics of Patients in the ICU With Palliative Care Consults in a Tertiary University Hospital

NCT06984471

The aim of this retrospective observational single-center cohort study is to investigate the factors associated with palliative care (PC) referral, examine intensive care unit (ICU) involvement before, during, or after the referral, and evaluate patient outcomes such as mortality, hospital and ICU length of stay, discharge destination, functional status, symptom management, and the content of PC consultation reports.

Palliative Care Referral

University Hospital, Basel, Switzerland532 participantsStarted May 2025

Basel, Switzerland

RECRUITINGPhase 1

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

NCT03219450

This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab

Lymphocytic Leukemia

Dana-Farber Cancer Institute15 participantsStarted Aug 2021

Boston, Massachusetts, United States

Active Not RecruitingPhase 1

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534

This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have spread to other places in the body (advanced). Gemcitabine is a chemotherapy drug that blocks the cell from making DNA and may kill tumor cells. elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and elimusertib in combination may shrink or stabilize cancer.

Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma+19 more

National Cancer Institute (NCI)14 participantsStarted Jun 2021

Bethesda, Maryland, United States • Bethesda, Maryland, United States • Boston, Massachusetts, United States

Characteristics of Patients in the ICU With Palliative Care Consults in a Tertiary University Hospital

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Related Searches

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Technology-Based Intervention for Reducing Sexually Transmitted Infections and Substance Use During Pregnancy

The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Central Venous Pressure and Right Atrial Pressure Measurements in Supine, Semi-recumbent and Trendelenburg Position

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

TGRX-326 Pharmacokinetic Food Effect Bioavailability Study

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer